title: Lipoprotein(a) in type 1 diabetic patients with renal disease.
abstract: Lp(a) was measured in 64 normoalbuminuric, 52 microalbuminuric, and 37 proteinuric Type 1 diabetic patients and 54 healthy subjects. Microalbuminuric and proteinuric Type 1 diabetic patients had higher median Lp(a) values (133 (16-1932) and 169 (17-1149) mg l-1) than patients with normal AER (73 (15-1078) mg l-1; p = 0.048 and p = 0.027). Lp(a) in healthy subjects (110 (15-1630)mg l-1) did not differ from the diabetic subgroups. The frequency of Lp(a) values in the upper quarter of the normal distribution was similar in the diabetic groups and did not differ between diabetic and control subjects. The cumulative distribution of Lp(a) was similar in all groups. Lp(a) concentrations were not related to AER, age, gender, duration of diabetes, body mass index, glycaemic control, serum creatinine, free insulin or systolic blood pressure. Cholesterol, LDL-cholesterol, triglycerides, and apo B were higher in microalbuminuric and proteinuric than in normoalbuminuric Type 1 diabetic patients. Lp(a) was independently related to diastolic blood pressure, fibrinogen, and macroangiopathy. In conclusion, median Lp(a) concentrations tend to be higher in Type 1 diabetic patients with early and established renal disease, although the differences are small and the overlap between groups large. Lp(a) is related to diastolic blood pressure and fibrinogen, and this association of powerful risk factors suggests that Lp(a) may play a role in the pathogenesis of cardiovascular disease in Type 1 diabetic patients with proteinuria. Whether Lp(a) is an independent determinant of increased cardiovascular risk in these patients needs to be elucidated by prospective studies.
authors.affiliation: Unit for Metabolic Medicine, United Medical School, Guy's Hospital, London, England.
authors.forename: P H
authors.initials: PH
authors.lastname: Groop
authors.forename: G C
authors.initials: GC
authors.lastname: Viberti
authors.forename: T G
authors.initials: TG
authors.lastname: Elliott
authors.forename: R
authors.initials: R
authors.lastname: Friedman
authors.forename: A
authors.initials: A
authors.lastname: Mackie
authors.forename: C
authors.initials: C
authors.lastname: Ehnholm
authors.forename: M
authors.initials: M
authors.lastname: Jauhiainen
authors.forename: M R
authors.initials: MR
authors.lastname: Taskinen
mesh_terms: D000328:Adult; D000419:Albuminuria / Q000097:blood* / Q000209:etiology; D001055:Apolipoproteins B / Q000097:blood; D002318:Cardiovascular Diseases / Q000150:complications; D016022:Case-Control Studies; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000150:complications; D016883:Diabetic Ketoacidosis; D003928:Diabetic Nephropathies / Q000097:blood* / Q000209:etiology; D005260:Female; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male
chemical_list: D001055:Apolipoproteins B; D017270:Lipoprotein(a)